Interference of neutrophil-platelet interaction by YC-1: a cGMP-dependent manner on heterotypic cell-cell interaction
Chang-Hui Liao1, Jun-Ting Cheng, Che-Ming Teng
1Graduate Institute of Natural Products, College of Medicine Chang Gung University No 259 Wen-Hwa 1st Road, Kwei-Shan, Tao-Yuan county, 333 Taiwan, Republic of China. liaoch@mail.cgu.edu.tw
Abstract:
N-Formyl-Met-Leu-Phe (fMLP) activated neutrophils and then induced neutrophil-platelet complex formation in co-incubation condition. In addition, fMLP induce intracellular calcium mobilization in platelets, only when it is incubated along with neutrophils. This data established that fMLP-stimulated neutrophils activate platelets. 9E1, a monoclonal antibody of P-selectin, significantly blocks the formation of neutrophil-platelet complex induced by fMLP, indicating the involvement of P-selectin in the neutrophil-platelet complex formation. 3-(5'-hydroxymethyl-2'-furyl-1-benzylindazole (YC-1), an unique nitric oxide-independent activator of soluble guanylate cyclase, was evaluated for its effect on neutrophil-platelet complex. YC-1 inhibits fMLP-induced neutrophil-platelet complex formation in a concentration-dependent manner with an IC50 value of 15.3+/-3.5 microM. However, this effect of YC-1 is partially reversed by pre-treatment of 1H-(1,2,4)oxadiazolo[4,3-a]quinozalin-1-one (ODQ; 10 microM), which is a soluble guanylate cyclase inhibitor. Pre-treatment of either neutrophils or platelets with YC-1 (50 microM) prevent the fMLP-induced neutrophil-platelet complex formation, indicating that YC-1 could potentially exert its effects individually on either neutrophils or platelets alone. Cathepsin G released from fMLP-stimulated neutrophil activates the nearby platelets. YC-1 was also shown to inhibit this release of cathepsin G in a concentration-dependent manner. The IC50 value was 6.2+/-0.2 microM. This inhibitory effect of YC-1 on cathepsin G release is reversed by ODQ (10 microM) and a protein kinase G inhibitor [1-oxo-9.12-epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-l][1,6]benzodiazocine-10-carbooxylic acid methyl ester (KT5835); 1 microM]. YC-1 inhibits cathepsin G-induced P-selectin expression on human platelet at the IC50 value of 32.5+/-2.6 microM. A further study showed that YC-1 inhibits fMLP-induced neutrophil-platelet complex formation in whole blood at the IC50 value of 35.8+/-8.1 microM in a concentration-dependent manner. According to these data, it was hypothesized that fMLP stimulates neutrophils to release cathepsin G, which subsequently activates the nearby platelets, creating neutrophil-platelet complexes. YC-1 inhibits fMLP-induced neutrophil from releasing cathepsin G via a cGMP-dependent pathway. This inhibitory effect of YC-1 on cathepsin G release is a major mechanism for affecting fMLP-induced neutrophil-platelet complex. YC-1's inhibition P-selectin expression on platelet may potentiate its effects. These inhibitory effects may contribute to the inhibition of neutrophil-platelet complex formation in whole blood.
Insights
N-Formyl-Met-Leu-Phe (fMLP) stimulates neutrophils to release cathepsin G, activating platelets and forming neutrophil-platelet complexes. YC-1 inhibits this process via a cGMP-dependent pathway, reducing complex formation.
Area of Science:
- Immunology
- Hematology
- Pharmacology
Background:
- Neutrophil-platelet complex formation is induced by N-Formyl-Met-Leu-Phe (fMLP).
- fMLP-stimulated neutrophils activate platelets, involving P-selectin.
- Cathepsin G released from neutrophils activates platelets, contributing to complex formation.
Purpose of the Study:
- To investigate the inhibitory effects of YC-1 on fMLP-induced neutrophil-platelet complex formation.
- To elucidate the underlying mechanisms of YC-1's action, including its effect on cathepsin G release and P-selectin expression.
- To evaluate YC-1's efficacy in whole blood models.
Main Methods:
- Co-incubation of neutrophils and platelets with fMLP.
- Assessment of intracellular calcium mobilization in platelets.
- Inhibition studies using monoclonal antibody 9E1 (anti-P-selectin).
- Evaluation of YC-1, ODQ (guanylate cyclase inhibitor), and KT5835 (protein kinase G inhibitor).
- Measurement of cathepsin G release and P-selectin expression.
- Experiments conducted in whole blood.
Main Results:
- YC-1 inhibited fMLP-induced neutrophil-platelet complex formation in a concentration-dependent manner (IC50 = 15.3 µM).
- YC-1 inhibited fMLP-induced cathepsin G release (IC50 = 6.2 µM) and cathepsin G-induced P-selectin expression on platelets (IC50 = 32.5 µM).
- Inhibitory effects of YC-1 were partially reversed by ODQ and KT5835, suggesting a cGMP-dependent pathway.
- YC-1 demonstrated efficacy in inhibiting neutrophil-platelet complex formation in whole blood (IC50 = 35.8 µM).
Conclusions:
- YC-1 effectively inhibits fMLP-induced neutrophil-platelet complex formation.
- The primary mechanism involves YC-1 inhibiting cathepsin G release from neutrophils via a cGMP-dependent pathway.
- YC-1's inhibition of P-selectin expression on platelets may further contribute to its overall effect.
- YC-1 shows potential as a therapeutic agent for conditions involving neutrophil-platelet activation.
Related Concept Videos
Intracellular Signaling Affects Focal Adhesions
Some...
GPCRs Regulate Adenylyl Cylase Activity
Two...
Nitric Oxide Signaling Pathway


